Epilepsy treatment by sacrificing vitamin D

Expert Review of Neurotherapeutics

Volumn 14, Issue 5, 2014, Pages 481-491

  Cebeci, Ayşe Nurcan ^a   Ekici, Bariş ^a  

^a Derince Training and Research Hospital   (Turkey)

Author keywords

antiepileptic therapy; bone health; children; epilepsy; vitamin D deficiency

Indexed keywords

ANTICONVULSIVE AGENT; VITAMIN D;

ANTICONVULSANT THERAPY; BONE HEALTH; BRAIN; CHILD HEALTH; EPILEPSY; HUMAN; POPULATION RESEARCH; REVIEW; SYNTHESIS; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; CHEMICALLY INDUCED; METABOLISM;

ANTICONVULSANTS; EPILEPSY; HUMANS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84899107136     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2014.905742     Document Type: Review

References (94)

1. Bhalla D, Godet B, Druet-Cabanac M, Preux PM. Etiologies of epilepsy: a comprehensive review. Expert Rev Neurother 2011;11(6):861-76
2. Geerts A, Arts WF, Stroink H, et al. Course and outcome of childhood epilepsy: a 15-year follow-up of the Dutch Study of Epilepsy in Childhood. Epilepsia 2010; 51(7):1189-97
3. Sillanpää M, Schmidt D. Predicting antiepileptic drug response in children with epilepsy. Expert Rev Neurother 2011;11(6): 877-85
4. Aronson E, Stevenson SB. Bone health in children with cerebral palsy and epilepsy. J Pediatr Health Care 2012;26(3):193-9
5. Sellier E, Uldall P, Calado E, et al. Epilepsy and cerebral palsy: characteristics and trends in children born in 1976-1998. Eur J Paediatr Neurol 2012;16(1): 48-55
6. Misra M, Pacaud D, Petryk A, et al. Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics 2008; 122(2):398-417
7. Rosen CJ. Clinical practice. Vitamin D insufficiency. N Engl J Med 2011;364(3): 248-54
8. Wagner CL, Greer FR. American Academy of Pediatrics Section on Breastfeeding; American Academy of Pediatrics Committee on Nutrition. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics 2008;122(5): 1142-52
9. Norris JM. Can the sunshine vitamin shed light on type 1 diabetes? Lancet 2001; 358(9292):1476-8
10. Sakaki T, Kagawa N, Yamamoto K, Inouye K. Metabolism of vitamin D3 by cytochromes P450. Front Biosci 2005;10: 119-34
11. Fraser DR. Vitamin D. Lancet 1995; 345(8942):104-7
12. Braegger C, Campoy C, Colomb V, et al. ESPGHAN Committee on Nutrition. Vitamin D in the healthy European paediatric population. J Pediatr Gastroenterol Nutr 2013;56(6):692-701
13. Hamed SA. Influences of bone and mineral metabolism in epilepsy. Expert Opin Drug Saf 2011;10(2):265-80
14. Mintzer S, Boppana P, Toguri J, DeSantis A. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia 2006;47(3):510-15
15. DeLuca HF. Evolution of our understanding of vitamin D. Nutr Rev 2008;66(10 Suppl 2):73-87
16. Pike JW, Meyer MB. The vitamin D receptor: new paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin D(3). Endocrinol Metab Clin North Am 2010;39(2):255-69
17. Wang Y, Zhu J, DeLuca HF. Where is the vitamin D receptor? Arch Biochem Biophys 2012;523(1):123-33
18. Bouillon R, Carmeliet G, Verlinden L, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008;29(6):726-76
19. Holick MF. Resurrection of vitamin D deficiency and rickets. J Clin Invest 2006; 116(8):2062-72
20. Wang Z, Lin YS, Zheng XE, et al. An inducible cytochrome P450 3A4-dependent vitamin D catabolic pathway. Mol Pharmacol 2012;81(4):498-509
21. Zhou C, Assem M, Tay JC, et al. Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest 2006;116(6): 1703-12
22. Wrzosek M, Łukaszkiewicz J, Wrzosek M, et al. Vitamin D and the central nervous system. Pharmacol Rep 2013;65(2):271-8
23. Brown J, Bianco JI, McGrath JJ, Eyles DW. 1,25-Dihydroxyvitamin D3 induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons. Neurosci Lett 2003; 343(2):139-43
24. Burkert R, McGrath J, Eyles D. Vitamin D receptor expression in the embryonic rat brain. Neurosci Res Commun 2003;33(1): 63-71
25. Eyles D, Burne T, McGrath J. Vitamin D in fetal brain development. Semin Cell Dev Biol 2011;22(6):629-36
26. Garcion E, Thanh XD, Bled F, et al. 1,25-Dihydroxyvitamin D3 regulates gamma 1 transpeptidase activity in rat brain. Neurosci Lett 1996;216(3):183-6
27. Harms LR, Eyles DW, McGrath JJ, et al. Developmental vitamin D deficiency alters adult behaviour in 129/SvJ and C57BL/6J mice. Behav Brain Res 2008;187(2): 343-50
28. McGrath JJ, Eyles DW, Pedersen CB, et al. Neonatal vitamin D status and risk of schizophrenia: a population-based case-control study. Arch Gen Psychiatry 2010;67(9):889-94
29. McGrath J, Saari K, Hakko H, et al. Vitamin D supplementation during the first year of lifeand risk of schizophrenia: a Finnish birth cohort study. Schizophr Res 2004;67(2-3):237-45
30. Smolders J, Damoiseaux J, Menheere P, Hupperts R. Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol 2008;194(1-2):7-17
31. Lefebvre d'Hellencourt C, Montero-Menei CN, Bernard R, Couez D. Vitamin D3 inhibits proinflammatory cytokines and nitric oxide production by the EOC13 microglial cell line. J Neurosci Res 2003;71(4):575-82
32. Christiansen C, Rodbro P, Sjö O. Anticonvulsant action of vitamin D in epileptic patients? A controlled pilot study. Br Med J 1974;2(5913):258-9
33. Kalueff AV, Minasyan A, Keisala T, et al. Increased severity of chemically induced seizures in mice with partially deleted vitamin D receptor gene. Neurosci Lett 2006;394(1):69-73
34. Kalueff AV, Minasyan A, Tuohimaa P. Anticonvulsant effects of 1,25-dihydroxyvitamin D in chemically induced seizures in mice. Brain Res Bull 2005;67(1-2):156-60
35. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol 2009;19(2):73-8
36. Snellman G, Melhus H, Gedeborg R, et al. Determining vitamin D status: a comparison between commercially available assays. PLoS One 2010;5(7): e11555
37. Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 1997;7(5):439-43
38. Seamans KM, Cashman KD. Existing and potentially novel functional markers of vitamin D status: a systematic review. Am J Clin Nutr 2009;89(6):1997S-2008S
39. Bischoff-Ferrari HA, Dietrich T, Orav EJ, Dawson-Hughes B. Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med 2004;116(9):634-9
40. Heaney RP, Dowell MS, Hale CA, Bendich A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 2003;22(2):142-6
41. Thacher TD, Fischer PR, Pettifor JM, et al. Radiographic scoring method for the assessment of the severity of nutritional rickets. J Trop Pediatr 2000;46(3):132-9
42. Vieth R, Ladak Y, Walfish PG. Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J Clin Endocrinol Metab 2003;88(1):185-91
43. Dawson-Hughes B, Mithal A, Bonjour JP, et al. IOF position statement: vitamin D recommendations for older adults. Osteoporos Int 2010;21(7):1151-4
44. Mithal A, Wahl DA, Bonjour JP, et al. IOF Committee of Scientific Advisors (CSA) Nutrition Working Group. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int 2009; 20(11):1807-20
45. Palacios C, Gonzalez L. Is vitamin D deficiency a major global public health problem? J Steroid Biochem Mol Biol 2013; S0960-0760(13):00233-1
46. Kumar J, Muntner P, Kaskel FJ, et al. Prevalence and associations of 25-hydroxyvitamin D deficiency in US children: NHANES 2001-2004. Pediatrics 2009;124(3):e362-70
47. Ahmed SF, Franey C, McDevitt H, et al. Recent trends and clinical features of childhood vitamin D deficiency presenting to a children's hospital in Glasgow. Arch Dis Child 2011;96(7):694-6
48. Beck-Nielsen SS, Jensen TK, Gram J, et al. Nutritional rickets in Denmark: a retrospective review of children's medical records from 1985 to 2005. Eur J Pediatr 2009;168(8):941-9
49. Lapatsanis D, Moulas A, Cholevas V, et al. Vitamin D: a necessity for children and adolescents in Greece. Calcif Tissue Int 2005;77(6):348-55
50. Akman AO, Tumer L, Hasanoglu A, et al. Frequency of vitamin D insufficiency in healthy children between 1 and 16 years of age in Turkey. Pediatr Int 2011;53(6): 968-73
51. Rodriguez-Rodriguez E, Aparicio A, Lopez-Sobaler AM, et al. Vitamin D status in a group of Spanish school children. Minerva Pediatr 2011;63(1):11-18
52. Offermann G, Pinto V, Kruse R. Antiepileptic drugs and vitamin D supplementation. Epilepsia 1979;20(1):3-15
53. Nettekoven S, Ströhle A, Trunz B, et al. Effects of antiepileptic drug therapy on vitamin D status and biochemical markers of bone turnover in children with epilepsy. Eur J Pediatr 2008;167(12):1369-77
54. Shellhaas RA, Barks AK, Joshi SM. Prevalence and risk factors for vitamin D insufficiency among children with epilepsy. Pediatr Neurol 2010;42(6):422-6
55. Misra A, Aggarwal A, Singh O, Sharma S. Effect of carbamazepine therapy on vitamin D and parathormone in epileptic children. Pediatr Neurol 2010;43(5):320-4
56. Aksoy A, Sönmez FM, Deger O, et al. The effects of antiepileptic drugs on the relationships between leptin levels and bone turnover in prepubertal children with epilepsy. J Pediatr Endocrinol Metab 2011; 24(9-10):703-8
57. Borusiak P, Langer T, Heruth M, et al. Antiepileptic drugs and bone metabolism in children: data from 128 patients. J Child Neurol 2013;28(2):176-83
58. Rieger-Wettengl G, Tutlewski B, Stabrey A, et al. Analysis of the musculoskeletal system in children and adolescents receiving anticonvulsant monotherapy with valproic acid or carbamazepine. Pediatrics 2001; 108(6):E107
59. Verrotti A, Greco R, Latini G, et al. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 2002;43(12): 1488-92
60. El-Hajj Fuleihan G, Dib L, Yamout B, et al. Predictors of bone density in ambulatory patients on antiepileptic drugs. Bone 2008;43(1):149-55
61. Fong CY, Riney CJ, Vitamin D. Deficiency Among Children With Epilepsy in South Queensland. J Child Neurol 2014;29(3): 368-73.
62. Nicolaidou P, Georgouli H, Kotsalis H, et al. Effects of anticonvulsant therapy on vitamin D status in children: prospective monitoring study. J Child Neurol 2006; 21(3):205-9
63. Pack AM. Treatment of epilepsy to optimize bone health. Curr Treat Options Neurol 2011;13(4):346-54
64. Volpe SL, Schall JI, Gallagher PR, et al. Nutrient intake of children with intractable epilepsy compared with healthy children. J Am Diet Assoc 2007;107(6):1014-18; 64
65. Alemzadeh R, Kichler J, Babar G, Calhoun M. Hypovitaminosis D in obese children and adolescents: relationship with adiposity, insulin sensitivity, ethnicity, and season. Metabolism 2008;57(2):183-91
66. Lagunova Z, Porojinicu AC, Lindberg FA, et al. Vitamin D status in Norwegian children and adolescents with excess body weight. Pediatr Diabetes 2011;12(2): 120-6
67. Daniels ZS, Nick TG, Liu C, et al. Obesity is a common comorbidity for pediatric patients with untreated, newly diagnosed epilepsy. Neurology 2009;73(9):658-64
68. Bergqvist AG, Schall JI, Stallings VA. Vitamin D status in children with intractable epilepsy, and impact of the ketogenic diet. Epilepsia 2007;48(1):66-71
69. Baer MT, Kozlowski BW, Blyler EM, et al. Vitamin D, calcium, and bone status in children with developmental delay in relation to anticonvulsant use and ambulatory status. Am J Clin Nutr 1997; 65(4):1042-51
70. Turner Z, Kossoff EH. The ketogenic and Atkins diet: recipes for seizure control. Pract Gastroenterol 2006;30:53-64
71. Bergqvist AG, Schall JI, Stallings VA, Zemel BS. Progressive bone mineral content loss in children with intractable epilepsy treated with the ketogenic diet. Am J Clin Nutr 2008;88(6):1678-84
72. Shellhaas RA, Joshi SM. Vitamin D and bone health among children with epilepsy. Pediatr Neurol 2010;42(6):385-93
73. Zhou C, Assem M, Tay JC, et al. Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest 2006;116(6): 1703-12
74. Kitanaka S, Isojima T, Takaki M, et al. Association of vitamin D-related gene polymorphisms with manifestation of vitamin D deficiency in children. Endocr J 2012;59(11):1007-14
75. Liu YZ, Liu YJ, Recker RR, Deng HW. Molecular studies of identification of genes for osteoporosis: the 2002 update. J Endocrinol 2003;177(2):147-96
76. Lambrinoudaki I, Kaparos G, Armeni E, et al. BsmI vitamin D receptor's polymorphism and bone mineral density in men and premenopausal women on long-term antiepileptic therapy. Eur J Neurol 2011;18(1):93-8
77. Phabphal K, Geater A, Limapichart K, et al. The association between BsmI polymorphism and bone mineral density in young patients with epilepsy who are taking phenytoin. Epilepsia 2013;54(2): 249-55
78. Peterson P, Gray P, Tolman KG. Calcium balance in drug-induced osteomalacia: response to vitamin D. Clin Pharmacol Ther 1976;19(1):63-7
79. Oner N, Kaya M, Karasalihoǧlu S, et al. Bone mineral metabolism changes in epileptic children receiving valproic acid. J Paediatr Child Health 2004;40(8): 470-3
80. Babayigit A, Dirik E, Bober E, Cakmakci H. Adverse effects of antiepileptic drugs on bone mineral density. Pediatr Neurol 2006;35(3): 177-81
81. Verrotti A, Agostinelli S, Coppola G, et al. 12-month longitudinal study of calcium metabolism and bone turnover during valproate monotherapy. Eur J Neurol 2010; 17(2):232-7
82. Tekgul H, Serdaroglu G, Huseyinov A, Gökben S. Bone mineral status in pediatric outpatients on antiepileptic drug monotherapy. J Child Neurol 2006;21(5): 411-14
83. Erbayat Altay E, Serdaroǧlu A, Tümer L, et al. Evaluation of bone mineral metabolism in children receiving carbamazepine and valproic acid. J Pediatr Endocrinol Metab 2000;13(7): 933-9
84. Wu S, Legido A, De Luca F. Effects of valproic acid on longitudinal bone growth. J Child Neurol 2004;19(1):26-30
85. Guo CY, Ronen GM, Atkinson SA. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 2001;42(9):1141-7
86. Cansu A, Yesilkaya E, Serdaroǧlu A, et al. Evaluation of bone turnover in epileptic children using oxcarbazepine. Pediatr Neurol 2008;39(4):266-71
87. Pack AM, Morrell MJ, Marcus R, et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol 2005;57(2):252-7
88. Pack AM, Morrell MJ, McMahon DJ, Shane E. Normal vitamin D and low free estradiol levels in women on enzyme - inducing antiepileptic drugs. Epilepsy Behav 2011;21(4):453-8
89. Kim SH, Lee JW, Choi KG, et al. A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy. Epilepsy Behav 2007;10(2): 291-5
90. Rauchenzauner M, Griesmacher A, Tatarczyk T, et al. Chronic antiepileptic monotherapy, bone metabolism, and body composition in non-institutionalized children. Dev Med Child Neurol 2010; 52(3):283-8
91. Disthabanchong S, Radinahamed P, Stitchantrakul W, et al. Chronic metabolic acidosis alters osteoblast differentiation from human mesenchymal stem cells. Kidney Int 2007;71(3):201-9
92. Ward KA, Das G, Berry JL, et al. Vitamin D status and muscle function in post-menarchal adolescent girls. J Clin Endocrinol Metab 2009;94(2):559-63
93. Tang J, Chonchol MB. Vitamin D and kidney stone disease. Curr Opin Nephrol Hypertens 2013;22(4):383-9
94. Kossoff EH, Pyzik PL, Furth SL, et al. Kidney stones, carbonic anhydrase inhibitors, and the ketogenic diet. Epilepsia 2002;43(10):1168-71